medigraphic.com
ISSN 3061-8142 (Electronic)
ISSN 0484-7903 (Print)

2025, Number 4

<< Back Next >>

Rev Mex Anest 2025; 48 (4)

Beyond tissue damage: nociplastic diseases and the emerging role of ketamine

Rascón-Martínez DM, Mendoza-Pineda L, Carrillo-Torres O

Language: Spanish
References: 32
Page: 229-235
PDF size: 628.19 Kb.


ABSTRACT

Nociplastic diseases are conditions characterized by the presence of persistent chronic pain despite the absence of clear evidence of actual or potential tissue damage that would trigger the activation of peripheral nociceptors, or evidence of disease or injury to the somatosensory system. This process of nociplasticity potentially leads to a state of heightened pain sensitivity or, alternatively, allodynia. It is estimated that approximately two-thirds of painful musculoskeletal disorders may be categorized within this class. These conditions pose challenges for healthcare professionals, as conventional therapies aimed at pain management often prove inadequate, and their presence marks a significant transformation in the perception and approach to chronic pain within the medical domain. A non-systematic review was conducted to understand the characteristics of ketamine for analgesia in various nociplastic diseases. This article aims to provide a descriptive review of the current literature on the role of ketamine in the treatment of chronic pain associated with nociplastic diseases. Additionally, the challenges and opportunities inherent in its application in the clinical context will be examined. The PICO methodology (P: population, I: intervention, C: comparison, and O: outcome) was employed for constructing the research question and conducting the literature search, where the population consisted of patients with nociplastic diseases, the intervention was the use of ketamine, no drugs or interventions were sought for comparison, and the outcomes were the efficacy in reducing nociplastic pain.


REFERENCES

  1. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161:1976-1982.

  2. Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice ASC, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157:1382-1386.

  3. Kohrs R, Durieux ME. Ketamine: teaching an old drug new trick. Anesth Analg. 1998;87:1186-1193.

  4. Orhurhu VJ, Roberts JS, Ly N, Cohen SP. Ketamine in acute and chronic pain management. 2022. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

  5. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481-486.

  6. Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81:886-897.

  7. Zhang N, Yao L, Wang P, Liu Z. Immunoregulation and antidepressant effect of ketamine. Transl Neurosci. 2021;12:218-236.

  8. Hiraga SI, Itokazu T, Nishibe M, Yamashita T. Neuroplasticity related to chronic pain and its modulation by microglia. Inflamm Regen. 2022;42:15.

  9. Atta AA, Ibrahim WW, Mohamed AF, Abdelkader NF. Microglia polarization in nociplastic pain: mechanisms and perspectives. Inflammopharmacology. 2023;31:1053-1067.

  10. Sunzini F, Schrepf A, Clauw DJ, Basu N. The biology of pain: through the rheumatology lens. Arthritis Rheumatol. 2023;75:650-660.

  11. Raja SN, Sivanesan E, Guan Y. Central sensitization, N-methyl-D-aspartate receptors, and human experimental pain models: bridging the gap between target discovery and drug development. Anesthesiology. 2019;131:233-235.

  12. Thompson T, Whiter F, Gallop K, Veronese N, Solmi M, Newton P, et al. NMDA receptor antagonists and pain relief. Neurology, 2019;92:e1652-e1662.

  13. Zhang H, Rodriguez-Hernandez LD, D'Souza AJ, He D, Zain M, Fung SW, et al. Nociceptor activity induces nonionotropic NMDA receptor signaling to enable spinal reconsolidation and reverse pathological pain. Sci Adv. 2023;9:2819.

  14. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.

  15. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.

  16. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. American Psychiatric Association (APA) council of research task force on novel biomarkers and treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74:399-405.

  17. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-964.

  18. De Kock M, Loix S, Lavand'homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther. 2013;19:403-410.

  19. Clarke M, Razmjou S, Prowse N, Dwyer Z, Litteljohn D, Pentz R, et al. Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. Neuropharmacology. 2017;112:210-220.

  20. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311:1547-1555.

  21. Herna?ndez-Porras BC, Plancarte-Sa?nchez R, Alarco?n-Barrios S Sa?mano-Garci?a M. Si?ndrome doloroso regional complejo: revisio?n. Cir Ciruj. 2017;85:366-374.

  22. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43:521-546.

  23. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous SM, Marinus J, Sarton EY, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145:304-311.

  24. Schwartzman RJ, Alexander GM, Grothusen JR. The use of ketamine in complex regional pain syndrome: possible mechanisms. Expert Rev Neurother. 2011;11:719-734.

  25. Pastrak M, Abd-Elsayed A, Ma F, Vrooman B, Visnjevac O. Systematic review of the use of intravenous ketamine for fibromyalgia. Ochsner J. 2021;21:387-394.

  26. Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80:642-647.

  27. Moisset X, Giraud P, Meunier E, Condé S, Périé M, Picard P, et al. Ketamine-Magnesium for refractory chronic cluster headache: a case series. Headache. 2020;60:2537-2543.

  28. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895-926.

  29. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77:357-367.

  30. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010;13:245-249.

  31. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Hauser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397:2098-2110.

  32. Cohen M, Quintner J, van Rysewyk S. Reconsidering the International Association for the Study of Pain definition of pain. Pain Rep. 2018;3:e634.




2020     |     www.medigraphic.com